As alternative transient repressors, antisense oligonucleotides (AON) were used to correct UCMD patient fibroblasts hosting a de novo dominant mutation in intron 9 of the COL6A2 gene (c.954+17_954+22del28) [13]. The gene discussed is COL6A2; the disease is Ullrich congenital muscular dystrophy.